The aim of this work was to improve the oral bioavailability of a recently discovered, novel structural class of 5-HT 1A receptor agonists: aryl-{[4-(6-R-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanone. Incorporation of a fluorine atom in the -position to the amino function in the side chain led to analogues that exhibited, in general, enhanced and longlasting 5-HT 1A agonist activity in rats after oral administration. Location of the fluorine atom at the C-4 position of the piperidine ring was the most favorable, and among the various substituents tested, the ability of the fluorine was unique in improving the oral activity of this family of ligands. Thus, the derivatives 39, 46, and 61 bound with higher affinity and selectivity to 5-HT 1A receptors (versus dopaminergic D 2 and adrenergic R 1 receptors) and displayed more potent 5-HT 1A agonist activity in vitro and in vivo than their C-4 desfluoro analogues. To examine the relationship between the conformation of the pharmacophore and the level of agonistic activity of this type of ligand, we synthesized a series of 3-chloro-4-fluorophenyl-(4-fluoro-4{[(5-(H or CH 3 )-6-R-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanone derivatives and found that the combination of a 5-methyl and a 6-methylamino substituent on the pyridine ring synergistically affected their 5-HT 1A agonist properties. Thus, the 3-chloro-4-fluorophenyl-(4-fluoro-4{[(5-methyl-6-methylamino-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanone 40 behaved as a more potent 5-HT 1A receptor agonist in vitro and in vivo than its 5-unsubstituted analogue 38. The antidepressant potential of the lead compounds 40, 45, and 54 was examined by means of the forced swimming test (FST) in rats. The results indicated that, after a single oral administration, these compounds inhibited immobility in the FST more potently and more extensively than the clinically used antidepressant imipramine. Thus, 40, 45, and 54 are potent, orally active 5-HT 1A receptor agonists with marked antidepressant potential.
Introduction
Many studies have focused on specific alterations of monoaminergic neurotransmission in depression. 1 The role of central serotoninergic (5-HT) systems, and in particular of 5-HT 1A receptor subtype-mediated neurotransmission, has attracted special interest over the last two decades. 2 However, the antidepressant effects of 5-HT 1A partial agonists, such as buspirone and ipsapirone, do not exceed those of currently available treatments, neither in terms of clinical efficacy 3 nor in terms of rapidity of onset. 4 It is conceivable that their limited clinical efficacy is related to their low level of intrinsic activity at 5-HT 1A receptors. 5 Thus, our research efforts are guided by the hypothesis that the antidepressant efficacy of 5-HT 1A agonists is a direct, positive function of their intrinsic activity, and therefore, aimed at discovering 5-HT 1A agonists with a high level of intrinsic activity. 6 In a recent paper, 7 we described a novel 5-HT 1A pharmacophore and reported a series of aryl-{[4-(6-Rpyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanones that bind with high affinity and selectivity to 5-HT 1A receptors. Of primary interest, several members of this series inhibited intracellular cAMP accumulation in forskolin-stimulated HA7 cells more potently and more extensively than the prototypical 5-HT 1A agonist (()-8-OH-DPAT. Unfortunately, despite their promising in vitro profiles, these compounds exerted only weak 5-HT 1A agonist activity in vivo, 8 possibly because of low bioavailability. Attempts to enhance the brain concentration of these novel 5-HT 1A agonists led to the design of a series of aryl-(4-fluoro-4{[(6-R-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl-methanones that exhibited very potent 5-HT 1A agonist properties, not only in vitro but also in vivo. Several of these compounds demonstrated marked antidepressant-like effects in the FST. 9 Finally, this novel series provided further insight into some of the structural determinants involved in the activation of 5-HT 1A receptors.
Chemistry
Compounds of the general formula 4 (Scheme 1, Table  7 ) were prepared from the appropriate pyridine-2-carboxaldehydes 3 either by reductive amination with primary amines of the type 1 (method A) or by an azaWittig reaction with azides of the type 2 (method B).
The synthesis of amines 1a, as shown in Scheme 2, began with acylation of the commercially available 4-piperidone-ethylene ketal by the appropriate aroyl chloride (NEt 3 , CH 2 Cl 2 , 0°C). After removal of the C-4 carbonyl protecting group, the oxirane function was installed by treatment of the piperidones 5 with dimethyloxosulfonium methylide, as described by Fishman 10 for the epoxidation of the N-benzyl-piperidone analogue. The spiro derivatives 6 underwent a regioselective ring-opening reaction with hydrogen fluoridepyridine complex 11 to afford the fluoro alcohol 7. The end of the synthesis was straightforward: the primary alcohol 7 was activated as the tosylate 8, which was then converted to the desired primary amine 1a via the phthalimide 9 (Gabriel synthesis). The 4-cyano-1-(3,4-dichloro-benzoyl)-piperidine-4-carboxylic acid ethyl ester 12 was used as the precursor to the amine 1b (Scheme 3). Thus, the ester function was first reduced to the alcohol 10 and then transformed into the triflate 11. Displacement of the triflate 11 by fluoride anion, under Grieco conditions, 13 provided the intermediate 12. Subsequent hydrogenation of the cyano group over Raney Ni gave the fluoromethylated amine 1b. The amine 1c (Scheme 4) was prepared by C-methylation of the lithium salt generated from 1-(3,4-dichloro-benzoyl)-piperidine-4-carbonitrile 14 (LDA, CH 3 I) followed by hydrogenation of the cyano group.
The azide 2a was obtained by ring-opening of epoxide 6 by NaN 3 (Scheme 5). Under standard conditions (NH 4 Cl, CH 3 OH/H 2 O), attack of the nucleophile occurred at the less substituted carbon exclusively. O-Methylation of the resulting -hydroxyazide 14 then yielded the azide 2a. The azide 2b could be derived from the intermediate 10 by the two-step sequence shown in Scheme 6.
The preparation of the 5-unsubstituted-6-substitutedpyridine-2-carboxaldehydes used in this work has been reported previously. 7 The synthesis of the novel 5-methyl-6-substituted-2-pyridinecarboxaldehydes was carried out as depicted in Scheme 7. The ester 16, obtained by the method of Hoornaert, 15 was reduced to the alcohol 17. Treatment of the latter with a large excess of methyl, ethyl, or dimethylamine under harsh reaction conditions led to the 6-alkylamino-5-methyl-2-pyridinemethanol derivatives 18a-c in moderate yields. Displacement of the 6-chlorine atom by amines was much more difficult than in the 5-unsubstituted series, demonstrating that the 5-methyl group has a pronounced effect on the reactivity of the pyridine ring. As a consequence, the derivative 18d, bearing a more hindered 6-diethylamino group, was best prepared from the intermediate 19, according to a variant also developed by Hoornaert. 16 Thus, treatment of the amidine 19 with DBU and ethanol (lactone cleavage and aromatization) gave the 6-diethylamino-5-methyl-pyridine-2-carboxylic acid ethyl ester (not shown in Scheme 7) which was reduced as described above (16 f 17) to afford the expected 6-diethylamino-5-methyl-2-pyridinemethanol 18d in modest overall yield. The primary alcohols 18a-d were subsequently oxidized to the target pyridine-2-carboxaldehydes 3a-d (MnO 2 /CHCl 3 ). 17 The synthetic sequence had to be modified slightly for the synthesis of the 6-pyrazol-1-yl-5-methyl-2-pyridinecarboxaldehyde 3e. Thus, the alcohol 17 was first oxidized and then the aldehyde function protected as the dioxolane 20. 18 Reaction of 20 with the sodium salt of pyrazole yielded the intermediate 21, which upon removal of the protecting group, afforded the desired 6-pyrazolo-5-methyl-pyridine-2-carboxaldehyde derivative 3e.
Pharmacology
Binding affinities for the different receptors were determined by means of ligand competition assays using the conditions summarized in the Experimental Section (Table 8) . All experiments were performed in triplicate. IC 50 values were determined using nonlinear regression. K i values were calculated using the equation 50 values for compounds were estimated by linear interpolation between the logarithms of the concentrations that inhibited forskolin-stimulated cAMP with amounts bordering 50% of the maximal inhibition observed with the compound. The potency and maximal inhibition values represent the mean of 2-4 independent determinations (each performed in triplicate) for all compounds, except (()-8-OH-DPAT whose values represent the mean of five determinations.
The methods used to examine the ability of compounds to produce lower lip retraction (LLR) in rats were the same as those described previously. 20 Rats were observed at two time points, centered at 15 and 60 min after the injection and each lasting 10 min. During a 10 min period, an animal was observed once every minute for 10 s and the presence (1) or absence (0) of LLR was recorded. Because an animal was observed 10 times during a 10 min period, the incidence of LLR could vary from 0 to 10. Dose-response functions were determined from the percentage of rats (n at least 2 per dose) showing LLR scores of 1 or more. This criterion was based on the incidence of LLR observed in control animals treated with saline, fewer than 5% of which had an LLR score of 1 or more; drugs were therefore considered to produce an effect in an individual animal when scores higher than zero were obtained. ED 50 estimates are obtained by linear interpolation. Because the pharmacological studies were conducted using doses differing by factor 4, the range of doses which encompassed the interpolated ED 50 values could not exceed this factor. Further, the coefficient of dispersion (i.e, ED 50 × 100/range) varied from 43 to 138%.
The forced swimming test was conducted in a manner similar to that described by Porsolt: 21 the procedure involved placing a rat in a cylinder (height: 45 cm, diameter: 20 cm) containing 17 cm water (25°C) for 15 min on the first day of the experiment and again in the cylinder 24 h later for 5 min. The duration of immobility during the 5 min period was measured by an observer who was unaware of the treatment conditions. Each animal was treated (volume: 10 mL/kg) with vehicle after the session on day 1 and, on day 2, with a particular dose of a test compound (n ) 10 per dose) or its vehicle control, given p.o. 60 min before placement in the cylinder. For each dose, the percentage inhibition of immobility was calculated by expressing the difference between the median immobility times of vehicle controls (i.e., 204 s) and of drug-treated animals as a percentage of the median immobility time of vehicle controls. In addition, dose-response functions were determined from the percentage of rats with an immobility time less than 138 s. Immobility times shorter than this criterion value occurred in less than 5% of the vehicle controls and were therefore considered significant. ED 50 estimates are obtained by linear interpolation.
Results and Discussion
Oxidative N-debenzylation is known to be a major biotransformation pathway for biogenic amines and nitrogen-containing xenobiotics. 22 Thus, we assumed that the pyridin-2-yl-methylamine fragment in structures such as 4 (Scheme 1; R 2 ) H) may be a likely target for redox active enzymes (cytochrome P 450's, MAO's ...). This assumption was supported by the finding that electron rich pyridine derivatives, even though being more potent to inhibit adenyl-cyclase in vitro than their electron deficient pyridine counterparts, displayed, in general, much weaker 5-HT 1A agonist activity in vivo. 23 The mechanism postulated for the benzylic C-N bond cleavage in compounds of type 4, catalyzed by oxido-reductases, involved a nitrogen radical cation in the first step ( Figure 1 ). Thus, we reasoned that an electronegative fluorine atom 24 in the -position to the benzylic amino function should (1) retard the oxidation-dependent processes by raising the redox potential of the secondary amino function (E N •• / N +• ) and (2) facilitate absorption by reducing the pK a of the secondary amine 25 and increasing the lipophilicity of the ligand. 26 There were two options available for introducing a fluorine atom in a suitable position relative to the secondary amino function: either at the C-4 of the piperidine ring or, in a vinylogous fashion, at C-3 of the pyridine nucleus. We examined the influence of fluorine incorporation in either of these positions. 27 The binding affinities of compounds 32 and 33 were only marginally improved by incorporation of a fluorine atom in either position (compared with 22 in Table 1 ). In contrast, 5-HT 1A agonist potency in vivo (ED 50 to induce LLR) increased markedly after i.p. and p.o. administration of the fluorinated derivative 32 as compared with the desfluoro compound 22. In particular, fluorine substitution for hydrogen at the Csp 3 -4 of the piperidine ring (32) provided a clear advantage in terms of in vivo activity (LLR, i.p. and p.o.) over its Csp 2 -3 location (33) . These findings prompted us to extend the Csp 3 -4 replacement of hydrogen by fluorine to other ligands of this family. 7 The compounds shown in Table 2 could be separated into two groups: (1) derivatives bearing an aliphatic amino substituent in the 6-position of the pyridine ring and (2) those having a five-membered heteroaromatic ring in this position. Within the first group (23-25, 28b Although the influence of the C-4 fluorine on the oral performance of the compounds shared the positive trend seen in the first group, there were marked differences among members of this group in terms of their in vitro potency (pEC 50 ). Thus, depending on the type of the heterocycle in the 6-position, the presence of the C-4 fluorine was either deleterious (56 and 57 versus 29 and 30), neutral (53 and 55 versus 26 and 27), or advantageous (61 versus 28). Such broad variations in potency data (over more than 1 log unit) suggested that the pattern of interactions used by these molecules to activate 5-HT 1A receptors may not overlap, notwithstanding they are structurally closely related.
The LLR activity of the desfluoro derivatives listed in Table 2 , except for 24, was sustained at 60 min after i.p. injection. Moreover, the ED 50 's to produce LLR were not, in general, dependent on the route of administration (26, 27, 29, and 30). Given these results, we assumed that low brain exposure was the major factor limiting the central activity of the C-4 desfluoro agonists. In this regard, ligands displaying comparable in vitro profiles but different in vivo activities, irrespectively of the nature of the C-4 substituent (H or F), told us about the pharmacokinetic input of the C-4 fluorine atom (e.g., 25 compared with 52, 28 versus 61, 26 versus 53, and 27 versus 55). Thus, it became clear that a C-4 fluorine has the ability to enhance concentration of the compound into the brain. Improved pharmacokinetics would be also one of the features that would, qualitatively, account for the greater in vivo effects produced in the more hydrophilic 6-amino ligands (e.g., 23, 24, 25 compared with 39, 46, 52, respectively). As discussed below, the contribution of the C-4 fluorine to the pharmacological profile of the ligand is, however, probably multifactorial. At present, even the possibility of specific metabolic activation of the fluorinated compounds cannot be ruled out. 29 Having identified several orally active 5-HT 1A agonists, we investigated various substituents at C-4 position to refine our understanding of the role of the fluorine atom. Depending on the nature of the R group at C-4, the affinity and the potency of compounds varied over 1 order of magnitude (Table 3 ). Various C-4 substitutents led to ligands with substantial affinity for, and agonist potency at, 5-HT 1A receptors (e.g., 31, 58, 65, 67, 68, and 69). Among them, however, only a fluorine atom was able to confer an in vivo activity to the compound exceeding that of the corresponding C-4 unsubstituted derivative (LLR of 58 versus 31). Moreover, changing the piperidine moiety by a tetrahydropyridine (69) was detrimental for recognition and activation of 5-HT 1A receptors, despite the fact that a Csp 2 -4 produced minimal steric hindrance, and generated a negative electrostatic potential around the C-4 region of the molecule which could mimic that of a fluorine atom. The contribution of the R group to 5-HT 1A binding is, therefore, best understood in terms of conformational distribution effects rather than in terms of specific interactions of the C-4 substituent with the receptor protein. Thus, if we assume that the variation of the affinity constants (K i ), throughout the homogeneous set of compounds shown in Table 3 , reflects the differences in the relative populations of molecules achieving active conformation(s), then it appears that the C-4 fluorine atom is able to select conformer(s) energetically close to the bioactive conformation(s) of the ligand. When R is small (R ) H; 31), or not sterically too demanding and inducing a strong permanent dipole moment (R ) F; 58), it tends to be axially oriented on the piperidine. 30 As a result, the piperidine ring is locked in (a) conformation(s) where the C-4 methylamino chain occupies an equatorial position. 31 Apparently, an intramolecular hydrogen bond between the fluorine atom and one of the vicinal ammonium protons did not participate in binding when the fluorine is directly attached to C-4 of the piperidine 32 (58 compared with 31). On the other hand, there may be some entropic contributions to binding of such a hydrogen bond in the higher homologue 68 (compared with 64).
The synergy seen in the desfluoro series, 7 between a few combinations of meta-para benzamide substituents, no longer occurred in the fluorinated series (Table  4) . Nonetheless, a 3-chloro, 4-fluoro-benzamide group (45) still had the best overall profile, in vitro and in vivo.
To examine the relationship between the conformation of the pharmacophore and the level of agonist activity, we prepared 5-methylated congeners of several 6-alkylamino and 6-heteroaromatic derivatives (Table  5 ). It was expected that, because of the presence of the 5-methyl group, the size of the 6-substituent would control the degree of planarity of the 6-substituentpyridine system: a n-π or p-π overlap should be allowed if the 6-substituents are small, but should become less favored as the size of the 6-substituents increases. Incorporation of a 5-methyl substituent in the 6-pyrazol- 3-yl-pyridine derivative 63 significantly decreased its 5-HT 1A affinity and potency (compared with 62). In contrast, the N-bound isomer 60 showed a pharmacological profile very similar to that of the 5-unsubstituted control 59. Thus, intriguingly, either the conformation of the pharmacophore plays a different role in C-bound (63) than in N-bound (60) aromatic 6-substituted ligands or the 5-methyl group reduces the steric tolerance in the region occupied by the 6-substituent only in C-bound 6-substituted derivatives. In all cases, the binding mode of the C-versus N-bound aromatic 6-substituted ligands at 5-HT 1A receptors is likely to be different.
The impact of an additional 5-methyl group in the nonaromatic 6-substituted series was more encouraging. For instance, the 5-methylated derivative 34 (Table 5) had 10 times higher affinity than its 5-unsubstituted congener 32 (Table 1) . Thus, clearly, the methyl group in the 5-position on the pyridine nucleus interacts with the receptor protein through hydrophobic effects.
When the methyl group was moved around the pyridine ring, affinity for 5-HT 1A receptors was retained but potency and in vivo activity were reduced markedly (47 and 48 compared with 49). In addition, in the 6-dialkylamino series, incorporation of a 5-methyl group did not seem to affect the in vitro responses of the corresponding ligands (49 and 51 compared with 45 and 50, respectively). This suggests that, in the 5,6-disubstituted series, the gain in free energy of stabilization of the receptor-ligand complex, provided by the 5-methyl effects, is partially offset by a less favorable contribution of the 6-substituents as compared to the 6-monosubstituted series, possibly for steric reasons.
Evidence in favor of such a scheme came from the 5-methyl-6-methylamino pyridine derivative 40. In this compound the 5-and the 6-substituents act synergistically, as shown by the substantial improvement of all the 5-HT 1A parameters over those of the 5-unsubstituted and the 6-dimethyl congeners (38 and 49, respectively). Hence, not only do the 5-and the 6-substituents in 40 (fully) cooperate in the stabilization of the receptorligand complex (i.e., gain in affinity) but, of prime interest, they seem to cooperate in the stabilization of a G-protein coupled state(s) of the receptor (i.e., gain in efficacy). Also consistent with the scheme proposed above, the steric constraints imposed on each component of the 5,6-pair are very tight. Thus, the synergistic effect between the 5-and the 6-groups vanished when the size of one of them was larger than a 5-methyl or a 6-methylamino group: the derivatives 36, 37, and 42 suffered marked losses in affinity and potency at 5-HT 1A receptors.
Compounds 40, 45 (Table 5) , and 54 (Table 2) , which emerged as the most active derivatives in each group, were then assessed in the FST. As summarized in Table  6 , all three compounds potently decreased immobility after a single administration, and maximal effects were greater than that of the tricyclic antidepressant imipramine. These novel 5-HT 1A receptor agonists have, therefore, the potential to exert antidepressant effects in humans. 33 Currently, these compounds, and others within this series, are being evaluated further in various preclinical models.
Conclusion
The present study is part of an effort to improve the in vivo properties of a recently described, novel class of 5-HT 1A receptor agonists. Here, we reported the preparation of, and discussed pharmacological results obtained with, a series of aryl- From a structural standpoint, a Csp 3 -4 fluorine atom proved unique in its ability to enhance the central 5-HT 1A activity of the ligands when administered orally. This effect may result from improved pharmacokinetics, possibly combined with some stereoelectronic contributing factors, rather than increased agonist properties of the fluorinated ligand at 5-HT 1A receptors. From a conformational standpoint, we proposed that the chain linked at C-4 on the piperidine ring assumed an equatorial or a pseudoequatorial orientation in the bioactive conformation(s) of the ligand.
The outstanding in vitro and in vivo profile of several compounds in this series, together with the novelty of their structures, warrants a further examination of their properties in other preclinical models. Already, these derivatives and analogues will provide innovative tools that could contribute to a better understanding of the therapeutic significance of 5-HT 1A receptors.
Experimental Section
Melting points were determined on a Bü chi 530 melting point apparatus and were not corrected. 1 After stirring for 17 h at room temperature, the solution was washed successively with 1 N HCl, H 2O, aqueous NaHCO3, and brine then dried and filtered. The solvent was evaporated under vacuum to give 172 g of the protected amide (quantitative) as an oil which was treated with 80% formic acid (500 mL) containing CuSO 4 (2 g) at 80°C for 16 h. Formic acid was eliminated by azeotropic distillation with toluene, and the oily residue obtained was neutralized with aqueous K2CO3. The mixture was extracted twice with CH2Cl2, dried, and filtered, and the solvent was evaporated to give an oil which crystallized on standing. Recrystallization from CH2Cl2-diisopropyl ether afforded 105 g of 5a (71.6%): mp 118-120°C; 1 
N-(3-Chloro-4-methylbenzoyl)-piperidin-4-one (5b).
This compound was prepared in 64% yield as described for 5a using 3-chloro-4-methylbenzoyl chloride as starting material. 5b was obtained as a white solid: mp 74-75°C; 1 H NMR (CDCl3) δ N-(3-Chlorobenzoyl)-piperidin-4-one (5d). This compound was prepared in 67% yield as described for 5a using 3-chlorobenzoyl chloride as starting material. Compound 5d was obtained as a white solid: mp 62-64°C; 1 
N-(3-Chloro-4-fluorobenzoyl)-1-oxa-6-azaspiro[2,5]-octane (6a).
A solution of dimethylsulfoxonium methylide was prepared, under nitrogen, from sodium hydride (1.52 g of a 60% dispersion in mineral oil, 37.8 mmol) and trimethylsulfoxonium iodide (8.32 g, 37.8 mmol) in anhydrous DMSO (20 mL). A solution of 5a (9.21 g, 36 mmol) in DMSO (20 mL) was added in 30 min and stirring was continued at 60°C for 3.5 h. The cooled reaction mixture was poured into ice-water and extracted twice with ethyl acetate. The combined organic layer was washed with water and brine and then dried and concentrated. The residue was purified by a short flash chromatography on silica gel, eluting with CHCl3-EtOAc (9: 1), to give 7.68 g of 6a (79%) as an oil which crystallized on standing: mp 75-77°C; 1 . This compound was prepared in 56% yield as described for 6a starting from 5d. Compound 6d was obtained as a pale yellow (CDCl3) δ 1.48 (m, 2H), 1.89 (m, 2H), 2.62 (s,  2H), 3.54 (m, 2H), 3.72 (m, 1H), 4.26 (m, 1H), 7.26-7.46 (m,  4H) .
N-(3-Chloro-4-fluorobenzoyl)-4-fluoro-4-hydroxymethylpiperidine (7a).
To a solution of the epoxide 6a (11.90 g, 44.1 mmol) and anhydrous CH2Cl2 (20 mL), stirred at -10°C, was added dropwise 70% poly(hydrogenfluoride)-pyridine (12.60 g, 441 mmol). The solution was stirred at -10°C for 15 min and then at room temperature for 16 h. The dark-red solution was poured into ice-water and carefully neutralized with K 2-CO3, and the product was extracted three times with CH2Cl2. The combined organic layer was washed with water, 1 N HCl, and brine and dried, and the solvent was evaporated off. The solid obtained was recrystallized from ethanol-ethyl acetate to give 6.40 g of 7a (50%) as a white solid: mp 188-190°C; , 1H), 7.35 (d, 2H), 7.48 (m, 2H), 7.78 (d, 2H) . , and anhydrous DMF (500 mL) was stirred at 150°C for 7 h. The cooled suspension was poured into ice-water and extracted twice with CH2Cl2. The combined organic layer was washed with brine, dried, and filtered through a pad of silica. Evaporation of the solvent gave an oil which crystallized upon addition of a mixture of diisopropyl ether-cyclohexane. Filtration of the solid gave 49.32 g of 9a (87%): mp 123-125°C; 1 H NMR (CDCl3) 1.85  (m, 4H), 3.16 (m, 1H), 3.34 (m, 1H), 3.65 (m, 1H), 3.91 (d, 2H) N-(3-Chlorobenzoyl)-4-fluoro-4-aminomethylpiperidine (1ad). This compound was prepared from 9d (87%) using the same procedure as described for the preparation of 1aa. Compound 1ad was obtained as a pale yellow oil: 1 H NMR (CDCl3) δ 1.35 (s broad, exchangeable), 1.61 (m, 2H), 1.93 (m,  2H), 2.80 (d, 2H), 3.25 (m, 2H), 3.65 (m, 1H), 4.54 (m, 1H),  7.28 (d, 1H), 7.39 (m, 3H). N-(3,4-Dichlorobenzoyl)-4-cyano, 4-hydroxymethylpiperidine (10). To a mixture of KBH4 (0.92 g, 17 mmol) , LiCl (0.73 g, 17.2 mmol), and anhydrous THF (30 mL) under a nitrogen atmosphere was added dropwise at room temperature a solution of N- (3,4-dichlorobenzoyl 08 mmol) and anhydrous THF (5 mL) was added dropwise to a suspension of HNa (60% dispersion in mineral oil, 0.365 g, 9.1 mmol) and THF (10 mL) under stirring and cooling in an ice-bath. Stirring was continued for 15 min at 0°C and for 1 h at room temperature. ICH3 (0.57 mL, 9.1 mmol) was added dropwise, and stirring was continued for 18 h at room temperature. The reaction mixture was poured in ice-water and extracted with EtOAc. The combined extracts were washed with water and brine, dried, and filtered, and the solvent was removed under vaccuum. The product was crystallized from hexane to give 5-Methyl-6-chloro-2-pyridinemethanol (17). To a solution of 5-methyl-6-chloro-2-pyridinecarboxylic acid ethyl ester 16 15 (8.80 g, 44 mmol) in ethanol (100 mL), maintained at room temperature, was added portionwise NaBH4 (2.80 g, 74 mmol), and the mixture was stirred overnight at room temperature. The suspension was concentrated under vacuum, poured into brine, and extracted twice with EtOAc. The organic layer was dried, filtered, and evaporated under vacuum to give 6.10 g of 17 (88%) as a pale yellow oil: 1 1H) .
N-(3-Chlorobenzoyl)-4-fluoro-4-(4-methylphenylsulfonyloxymethyl)-piperidine (8d)
5-Methyl-6-methylamino-2-pyridinemethanol (18a). A solution of 17 (3.49 g, 22 mmol) and methylamine (33% in ethanol, 27 mL), was heated at 100°C in a closed vessel for 48 h. After the mixture cooled to room temperature, the solvent was removed under vacuum and the residue extracted twice with EtOAc. The organic layer was washed with water and brine, dried, and filtered. The residue was purified by flash chromatography on silica gel, eluent EtOAc-cyclohexane (6: 4), to give 1.68 g of 18a (50%) as an oil which crystallized on standing: mp 86-88°C; 1 5-Methyl-6-diethylamino-2-pyridinemethanol (18d). To a solution of 4-chloro-6-diethylamino-1-methyl-2-oxa-5-azabicyclo[2.2.2]oct-5-en-3-one 19 16 (9.37 g, 39.6 mmol), DBU (22.4 mL, 159 mmol), and anhydrous THF (130 mL) at room temperature was added ethanol (2.77 mL, 47.5 mmol), and the mixture was heated under reflux for 24 h. The solvent was distilled under vacuum and the residue was poured into water and extracted twice with ethyl acetate. The combined organic layer was washed with brine and water, dried, filtered, and concentrated under vacuum. The crude product was purified by flash chromatography on silica gel, eluent cyclobexaneEtOAc (95:5), to afford 1.89 g of 5-methyl-6-diethylamino-2-pyridinecarboxylic acid ethyl ester as an oil. This oil was taken up in EtOH (25 mL), treated at room temperature with NaBH 4 (875 mg, 23 mmol), and then heated at reflux for 2 h. The solvent was distilled off, and the residue was taken up in icewater and then extracted twice with CH2Cl2. The organic layers were dried, filtered, and concentrated under vacuum. The residue was purified by flash chromatography on silica gel, eluent CH2Cl2-EtOAc (95:5), to give 0.92 of 18d (12%) as a pale yellow oil: 1 5-Methyl-6-methylamino-2-pyridinecarboxaldehyde (3a). To a solution of 18a (0.93 g, 6.11 mmol) and anhydrous CHCl 3 (20 mL) was added MnO2 (5 g, 57.5 mmol), and the suspension was stirred vigorously under reflux for 2 h. Insoluble material was filtered off, and then the compound was purified on a short silica gel column eluting with CHCl3. Removal of the solvent under vacuum gave 0.75 g of 3a (80%) as an oil which crystallized on standing: mp 78-80°C; 1 5-Methyl-6-(ethylamino)-2-pyridinecarboxaldehyde (3b). This compound was prepared in 50% yield as described for 3a using 18b as starting material. 5-Methyl-6-chloro-2-(1.3-dioxolan-2-yl)-pyridine (20) . To a solution of 17 (5.49 g, 34.8 mmol) and anhydrous CHCl3 (200 mL) was added MnO2 (26 g, 300 mmol), and the suspension was stirred under reflux for 3 h. Insoluble materials were filtered off, and then the compound was purified on a short silica gel column. The solvent was removed under vacuum to give 4.03 g of 5-methyl-6-chloro-2-pyridinecarboxaldehyde (74%) as an oil which crystallized on standing: mp 70-72°C; 1 5-Methyl-6-(pyrazol-2-yl)-2-pyridinecarboxaldehyde (3e). A suspension of 21 (0.60 g, 2.73 mmol), formic acid (4 mL), H 2O (1 mL), and CuSO4 (0.03 g) was stirred at 65°C for 2.5 h. The solution was concentrated under vacuum, and then the residual formic acid was eliminated by azeotropical distillation with toluene. The residue was taken up in ice-water, and an excess of K2CO3 was added. The product was extracted twice with EtOAc, washed with diluted NH4OH and brine, dried, and concentrated under vacuum. The product was purified by flash chromatography, eluent hexanes-EtOAc (80: 20) , to give 0.29 g of 3e (55%) as a pale yellow oil which crystallized on standing: mp 46-48°C; 1 
